Outcomes and prognostic factors in modern era management of major salivary gland cancer

被引:50
作者
Jegadeesh, Naresh [1 ,6 ]
Liu, Yuan [4 ,5 ,6 ]
Prabhu, Roshan S. [7 ]
Magliocca, Kelly R. [2 ,6 ]
Marcus, David M. [8 ]
Higgins, Kristin A. [1 ,6 ]
Vainshtein, Jeffrey M. [1 ,6 ]
Wadsworth, J. Trad [3 ,6 ]
Beitler, Jonathan J. [1 ,6 ]
机构
[1] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Otolaryngol, Atlanta, GA 30322 USA
[4] Emory Univ, Dept Biostat, Atlanta, GA 30322 USA
[5] Emory Univ, Dept Bioinformat, Atlanta, GA 30322 USA
[6] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[7] Levine Canc Inst, Southeast Radiat Oncol Grp, Charlotte, NC USA
[8] Valley View Hosp, Glenwood Springs, CO USA
关键词
Head and neck cancer; Salivary gland cancer; Radiation therapy; SQUAMOUS-CELL CARCINOMA; PHASE-II; MALIGNANT-TUMORS; POSTOPERATIVE RADIOTHERAPY; ONCOLOGY-GROUP; PAROTID-GLAND; UNITED-STATES; NECK-CANCER; HEAD; CHEMOTHERAPY;
D O I
10.1016/j.oraloncology.2015.05.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: There is a dearth of prospective evidence regarding cancer of the major salivary glands. Outcomes and management of major salivary gland are based largely on retrospective series spanning many decades and changes in surgical, radiation, imaging and systemic therapy strategies and technique. We sought to report contemporary patterns of relapse and prognostic factors for major salivary gland cancer. Materials and methods: 112 patients with major salivary gland cancers underwent resection with or without adjuvant therapy between January 1997 and September 2010. Outcomes were documented with follow-up until December 2014. Survival was calculated by the Kaplan-Meier method. Log-rank test and Cox proportional hazards regression were performed with locoregional control (LRC), distant control (DC) and overall survival (OS) as the primary outcome variables. Results: Median follow-up was 55.1 months. Rates of LRC for stage I/II and III/IV at five years were 95.7% and 61.9% respectively. Rates of DC at five years for stage I/II and III/IV were 93% and 56.9% respectively. Multivariate analysis identified larger tumor size, clinical nerve involvement and in parotid cancers, advanced T stage, no adjuvant radiation, and older age at diagnosis to be associated with increased risk of locoregional recurrence (all p < 0.05). Distant metastasis was associated with sublingual site, degree of clinical nerve involvement, high grade, tumor size and in parotid tumors additionally deep lobe involvement on multivariate analysis (all p < 0.05). Conclusion: Several prognostic factors were identified that may help guide decisions regarding adjuvant therapy. DM remains a significant concern in the management of this disease. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:770 / 777
页数:8
相关论文
共 30 条
[1]   Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands [J].
Agulnik, Mark ;
Cohen, Ezra W. E. ;
Cohen, Roger B. ;
Chen, Eric X. ;
Vokes, Everett E. ;
Hotte, Sebastien J. ;
Winquist, Eric ;
Laurie, Scott ;
Hayes, D. Neil ;
Dancey, Janet E. ;
Brown, Shirley ;
Pond, Gregory R. ;
Lorimer, Ian ;
Daneshmand, Manijeh ;
Ho, James ;
Tsao, Ming-Sound ;
Siu, Lillian L. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3978-3984
[2]  
ARMSTRONG JG, 1990, ARCH OTOLARYNGOL, V116, P290
[3]   Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer [J].
Bernier, J ;
Domenge, C ;
Ozsahin, M ;
Matuszewska, K ;
Lefèbvre, JL ;
Greiner, RH ;
Giralt, J ;
Maingon, P ;
Rolland, F ;
Bolla, M ;
Cognetti, F ;
Bourhis, J ;
Kirkpatrick, A ;
van Glabbeke, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1945-1952
[4]   Incidence of Carcinoma of the Major Salivary Glands According to the WHO Classification, 1992 to 2006: A Population-Based Study in the United States [J].
Boukheris, Houda ;
Curtis, Rochelle E. ;
Land, Charles E. ;
Dores, Graca M. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (11) :2899-2906
[5]   Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database [J].
Carvalho, AL ;
Nishimoto, IN ;
Califano, JA ;
Kowalski, LP .
INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (05) :806-816
[6]   Salivary gland cancers: current treatments, molecular characteristics and new therapies [J].
Chandana, Sreenivasa R. ;
Conley, Barbara A. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (04) :645-652
[7]   Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: Implications for adjuvant therapy [J].
Chen, Allen M. ;
Granchi, Phillip J. ;
Garcia, Joaquin ;
Bucci, M. Kara ;
Fu, Karen K. ;
Eisele, David W. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (04) :982-987
[8]   Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck [J].
Cooper, JS ;
Pajak, TF ;
Forastiere, AA ;
Jacobs, J ;
Campbell, BH ;
Saxman, SB ;
Kish, JA ;
Kim, HE ;
Cmelak, AJ ;
Rotman, M ;
Machtay, M ;
Ensley, JF ;
Chao, KSC ;
Schultz, CJ ;
Lee, N ;
Fu, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1937-1944
[9]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[10]   SALIVARY-GLAND TUMORS - A REVIEW OF 2410 CASES WITH PARTICULAR REFERENCE TO HISTOLOGICAL TYPES, SITE, AGE AND SEX DISTRIBUTION [J].
EVESON, JW ;
CAWSON, RA .
JOURNAL OF PATHOLOGY, 1985, 146 (01) :51-58